证券代码：688578 证券简称：艾力斯 公告编号：2024-028 上海艾力斯医药科技股份有限公司 关于参加 2024 年半年度科创板制药及生物制品专场 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海艾力斯医药科技股份有限公司（以下简称"公司"）已于 2024 年 8 月 21 日在上海证券交易所网站（www.sse.com.cn）披露公司 2024 年半年度报告， 为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况及 发展理念，在上海证券交易所的支持下，公司将参与由上海证券交易所主办的 2024 年半年度科创板制药及生物制品专场集体业绩说明会，就投资者关心的问 题进行交流。 三、参加人员 参加本次业绩说明会的人员包括：公司董事长兼总经理杜锦豪先生；公司财 务负责人王林先生；公司董事会秘书李硕女士；公司独立董事严骏先生（如有特 殊情况，参会人员可能进行调整）。 四、投资者参与方式 （一）投资者可在 2024 年 9 月 18 日(星期三)下午 14:00 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-027 上海艾力斯医药科技股份有限公司 关于与加科思签署药品技术许可与开发协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海艾力斯医药科技股份有限公司（以下简称"公司"）于 2024 年 8 月 30 日与北京加科思新药研发有限公司（以下简称"加科思"）签署《药品技术许 可与开发协议》。根据协议内容，加科思授予公司在中国（包括中国大陆、香港、 澳门和台湾地区）研究、开发、生产、注册以及商业化 KRAS G12C 抑制剂戈来 雷塞和 SHP2 抑制剂 JAB-3312 的独占许可。公司将就此项授权向加科思支付 1.5 亿元首付款，最高达 7.0 亿元的开发及销售里程碑付款，以及两位数比例的销售 提成，上述金额为含增值税金额。 本次交易未构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 本次交易已经公司第二届董事会第十次会议审议通过，无需提请公司股 东大会批准。 一、交易概况 公司于 2024 年 8 月 3 ...

Investment Rating - The report maintains an "Add" rating for the company [2][4][11] Core Insights - The company has demonstrated sustained high growth in revenue and profit, with a significant increase in sales driven by the product Vomeletin, which has been approved for first-line treatment of EGFR mutation NSCLC and included in the national medical insurance directory [6][7][9] - The company achieved a revenue of 1.576 billion yuan in the first half of 2024, representing a year-on-year increase of 111%, and a net profit attributable to shareholders of 656 million yuan, up 215% year-on-year [6][7][9] - The gross margin remains high at 95.63%, with a notable decrease in sales, management, and R&D expense ratios, showcasing the benefits of scale [9] Financial Performance Summary - For 2024, the company expects earnings per share (EPS) of 2.76 yuan, with projected EPS for 2025 and 2026 at 3.21 yuan and 3.70 yuan respectively, corresponding to price-to-earnings ratios of 20.1X, 17.2X, and 15.0X based on the closing price on August 20, 2024 [4][9] - The company has achieved a continuous increase in sales revenue for 10 consecutive quarters, with a quarter-on-quarter revenue growth of 12% in Q2 2024 [7][9] - The report highlights the successful expansion of the product pipeline, including clinical trials for various indications and collaborations to enhance market presence [8][9]

证券代码：艾力斯 证券简称：688578 上海艾力斯医药科技股份有限公司投资者关系活动记录表 （2024 年 8 月） □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投 资 者 关 系 活 □新闻发布会 □路演活动 动类别 □现场参观 √其他 投资者电话交流会 参 与 单 位 名 称 2024 年 8 月 21 日 15:00-16:00 及人员姓名 线上参会投资者： 3W 一位；AIHC 两位；Anatole 一位；Ariose Capital 一 位；KIM 韩国投信 一位；LMR 一位；Pinpoint 一位； Point72 一 位 ； SCHP 一 位 ； Superstring Capital 一 位 ； Temasek Fullerton Alpha Pte Ltd 一位；安和投资 一位；安 信基金 一位；安中投资 一位；奥博医疗 一位；奥博资本 一位；柏骏资本 一位；宝盈基金 一位；保银投资 一位； 1 / 20 彼得明奇基金 一位；博道基金 一位；博鸿投资 一位；博 普资产 一位；博时基金 一位；博衍基金 一位；博裕资本 一位；渤海人寿 一位；财达证券 一位；财通基金 一位； 财通 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3] Core Insights - The company reported a significant increase in revenue and net profit for H1 2024, with revenue reaching 1.58 billion yuan, up 110.6% year-on-year, and net profit of 660 million yuan, up 214.8% year-on-year [3] - The clinical potential of the drug Vomeletin continues to be explored, with recent approvals for various clinical trials, indicating strong future growth prospects [3] - The company is focused on innovative drug development in the oncology sector, particularly in non-small cell lung cancer (NSCLC), with a robust pipeline of targeted therapies [3] Financial Performance - For 2024, the company is projected to achieve revenues of 3.18 billion yuan, 3.59 billion yuan in 2025, and 4.01 billion yuan in 2026, with corresponding net profits of 1.03 billion yuan, 1.31 billion yuan, and 1.49 billion yuan respectively [3][5] - The expected price-to-earnings (PE) ratios for 2024, 2025, and 2026 are 21, 16, and 14 times respectively, indicating a favorable valuation trend [3][5] - The company has shown a consistent increase in research and development investment, with R&D expenses projected to reach 540.6 million yuan in 2024 [5] Market Position - The company has established a competitive advantage in the NSCLC targeted drug market, with a strong focus on innovative therapies and a growing pipeline [3] - The approval of IND applications for new drugs highlights the company's commitment to expanding its product offerings and addressing unmet medical needs in oncology [3][5]

证券代码：688578 证券简称：艾力斯 公告编号：2024-025 上海艾力斯医药科技股份有限公司 关于 2024 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 2024 年 1-6 月，公司合并财务报表归属于上市公司股东的净利润为人民币 656,136,849.43 元，截至 2024 年 6 月 30 日，母公司报表期末未分配利润为人民 币 645,099,363.36 元。经董事会决议，公司 2024 年半年度拟以实施权益分派股 权登记日登记的总股本为基数分配利润。本次利润分配方案如下： 公司拟向全体股东每 10 股派发现金红利 2.50 元（含税）。截至 2024 年 6 月 30 日，公司总股本 450,000,000 股，以此计算合计拟派发现金红利 112,500,000.00 元（含税），现金分红金额占公司 2024 年半年度合并报表中归属于上市公司股东 的净利润的比例为 17.15%。本次不送红股，不进行资本公积金转增股本。 如在本公告披 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $X million for the first half of 2024, representing a Y% growth compared to the same period last year[10]. - The company's total revenue for the first half of 2024 reached ¥1,576,480,088.85, representing a 110.57% increase compared to ¥748,674,712.29 in the same period last year[19]. - Net profit attributable to shareholders was ¥656,136,849.43, up 214.82% from ¥208,414,161.95 year-on-year[21]. - The basic earnings per share rose to ¥1.46, a 217.39% increase from ¥0.46 in the previous year[20]. - The net cash flow from operating activities increased by 293.73% to ¥730,267,159.10, primarily due to significant sales revenue from the core product, Furmonertinib[22]. - The company achieved total revenue of 1.576 billion RMB, representing a year-on-year growth of 110.57%[75]. - Net profit attributable to the parent company reached 656 million RMB, with a year-on-year increase of 214.82%[75]. - The net profit after deducting non-recurring gains and losses was CNY 646,879,800, reflecting a growth of 251.94% year-on-year[85]. Research and Development - The company has outlined its commitment to research and development of new drugs, particularly focusing on targeted therapies for cancer treatment[8]. - Research and development expenses amounted to ¥131,252,239.55, remaining stable year-on-year, with R&D expenses accounting for 8.33% of total revenue, a decrease of 9.33 percentage points[21]. - The company is actively developing several new drug candidates, including a fourth-generation EGFR-TKI and various inhibitors targeting PRMT5, KRAS, and p53, all aimed at treating solid tumors[25]. - The company’s research and development process covers all stages from drug discovery to post-marketing studies, ensuring a comprehensive approach to new drug development[41]. - The company’s R&D capabilities are focused on developing best-in-class and first-in-class drug molecules[60]. - The company has established a comprehensive drug development system covering all stages from discovery to commercialization, focusing on innovative oncology drugs[24]. - The company has signed a collaboration agreement with a partner for the exclusive commercialization rights of Pralsetinib capsules in mainland China, which is the first approved RET inhibitor in the region, targeting a market of approximately 10,000 new patients annually[37]. Market Outlook and Strategy - The company provided an optimistic outlook for the second half of 2024, projecting revenue growth of B% driven by new product launches and market expansion strategies[10]. - The company is focusing on expanding its market presence in D regions, aiming to increase market share by E% over the next year[10]. - A strategic acquisition was announced, which is expected to enhance the company's capabilities in the oncology sector and contribute an additional F million in revenue annually[11]. - The company is leveraging its strong sales capabilities in the lung cancer treatment field to maximize the market coverage of Pralsetinib capsules[42]. - The company is committed to ecological priority and green low-carbon development, enhancing environmental management and facilities during operations[105]. Corporate Governance and Compliance - The half-year report is unaudited, ensuring transparency in financial reporting[4]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[4]. - The report highlights various risk factors that the company may face during its operations, detailed in the "Management Discussion and Analysis" section[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[4]. - The company has maintained a good integrity status, with no court judgments unfulfilled or significant debts overdue during the reporting period[131]. Environmental and Social Responsibility - The company invested a total of ¥13,125.22 million in R&D projects during the reporting period, with cumulative investments reaching ¥133,616.19 million[66]. - The company has established mechanisms for environmental protection and complies with national environmental laws and regulations[103]. - The company has implemented carbon reduction measures, including a solar water heating system that saves approximately 60 tons of carbon emissions annually[104]. - The company promotes low-carbon awareness among employees through centralized and paperless offices, information meetings, and recycling initiatives[105]. Shareholder Information and Profit Distribution - The company plans to distribute a cash dividend of 2.50 RMB per 10 shares, totaling approximately 450 million RMB based on a total share capital of 112.5 million shares as of June 30, 2024[98]. - The company commits to not repurchase shares or transfer shares held before the public offering until it achieves profitability[115]. - The company's profit distribution policy emphasizes continuity and stability, considering long-term interests and sustainable development[117]. - Cash dividends will be prioritized when conditions are met, with a minimum distribution of 10% of the distributable profit if no major investment plans arise[118]. Legal and Regulatory Matters - The company reported significant legal proceedings, including an arbitration application filed by Jiangsu Fosun Pharmaceutical Sales Co., Ltd. regarding an exclusive promotion agreement, which has been accepted and is pending a hearing[131]. - There are no significant related party transactions reported during the period, and all transactions are conducted at market prices[132]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[130]. Financial Reporting and Audit - The financial statements were prepared in accordance with the Chinese Accounting Standards, ensuring compliance and accuracy[185]. - The company has not reported any non-standard audit opinions or issues from the previous annual report[130]. - The company recognizes expected credit losses for financial assets measured at amortized cost based on historical experience and future economic forecasts[195].

证券代码：688578 证券简称：艾力斯 公告编号：2024-024 上海艾力斯医药科技股份有限公司 2024年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要 求》、《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等有关 规定，上海艾力斯医药科技股份有限公司（以下简称"本公司"或"公司"）董 事会对 2024 年半年度募集资金存放与实际使用情况专项报告说明如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 根据中国证券监督管理委员会于 2020 年 10 月 12 日签发的证监许可 [2020]2559 号文《关于同意上海艾力斯医药科技股份有限公司首次公开发行股票 注册的批复》，公司在境内首次公开发行 90,000,000 股人民币普通股 A 股股票， 每股发行价格为人民币 22.73 元，股款以人民币缴足，计人民币 2,045,700,000.00 元，扣除承销及保荐费用、律师费、 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-023 上海艾力斯医药科技股份有限公司 第二届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海艾力斯医药科技股份有限公司（以下简称"公司"）第二届监事会第八 次会议于 2024 年 8 月 19 日在公司会议室召开。本次会议由监事会主席张晓芳女 士召集并主持，应到监事 3 人，实到监事 3 人；本次会议的召集和召开程序符合 《中华人民共和国公司法》等法律法规、规范性文件以及《公司章程》的相关规 定，会议形成的决议合法、有效。 二、 监事会会议审议情况 经与会监事审议，形成如下决议： （一）审议通过《关于公司<2024 年半年度报告>及其摘要的议案》 监事会对公司 2024 年半年度报告及其摘要进行了审核，并发表审核意见如 下： （1）公司 2024 年半年度报告编制和审议程序符合法律法规、公司章程和公 司内部管理制度的各项规定； （2）公司 2024 年半年度报告公允反映了报告期内的财务状况和经营成果， 所包 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-022 上海艾力斯医药科技股份有限公司 关于公司股东减持股份计划公告 股东上海艾祥企业发展中心（有限合伙）、上海艾耘企业发展中心（有限合 伙）保证向上海艾力斯医药科技股份有限公司提供的信息不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 公司董事会及全体董事保证公告内容与上述股东提供的信息一致。 重要内容提示： 股东持股的基本情况 截至本公告披露日，员工持股平台上海艾祥企业发展中心（有限合伙）（以 下简称"上海艾祥"）、上海艾耘企业发展中心（有限合伙）（以下简称"上海艾 耘"，上海艾祥、上海艾耘合称"员工持股平台"）分别持有公司股份 36,401,021 股、10,800,001 股，占公司总股本 8.09%、2.40%，为其于公司首次公开发行前取 得的股份，且已于 2023 年 12 月 4 日起上市流通。 减持计划的主要内容 二、减持计划的主要内容 员工持股平台上海艾祥、上海艾耘计划拟通过大宗交易方式减持其所持有的 公司股份合计不超过 4,500,000 股，拟减持股份占公司总股本的比例不超过 1.0 ...